Document Detail

The Safety and Tolerability of Ferric Citrate as a Phosphate Binder in Dialysis Patients.
MedLine Citation:
PMID:  23075669     Owner:  NLM     Status:  Publisher    
Background: A phase II open-label study was conducted in hemodialysis patients evaluating the short-term safety, tolerability, and iron absorption with ferric citrate when used as a phosphate binder. Methods: Enrollment occurred in two periods. Period 1 recruited patients taking 6-15 pills/day of binder with phosphorus of ≥2.5 mg/dl. Period 2 recruited patients taking ≥12 pills/day of binder with phosphorus of ≥3.5 mg/dl. Participants with ferritin ≥1,000 µg/l or transferrin iron saturation (TSAT) ≥50% at screening were excluded. Subjects discontinued their previous binders and started 4.5 g/day of ferric citrate (period 1) or 6 g/day (period 2) and were titrated for 4 weeks to maintain a phosphorus of 3.5-5.5 mg/dl. Chemistries and complete blood count were obtained weekly and a gastrointestinal questionnaire was administered at drug initiation and final visit. Iron therapy was permitted if the ferritin was <500 µg/l and TSAT <30%. Results: Fifty-five subjects were enrolled. Four serious adverse events were reported; none were related to the study drug. Findings from the gastrointestinal questionnaire included stool discoloration (69%), constipation (15%), and bloating (7%). Mean iron parameters at the beginning of the study were ferritin 554 ± 296 µg/l, iron 68 ± 21 µg/dl, and iron saturation 30 ± 7.8%. At the end of study, mean ferritin was 609 ± 340 µg/l (p = 0.02), iron 75 ± 27 µg/dl (p = 0.04), and TSAT was 35 ± 13% (p = 0.001). Mean phosphorus and calcium levels were unchanged from baseline at the end of study. Conclusion: Ferric citrate was well tolerated by patients after 4 weeks with no significant clinical or biochemical adverse events related to exposure.
Marvin Sinsakul; Mohammed Sika; Mark Koury; Warren Shapiro; Tom Greene; Jamie Dwyer; Mark Smith; Stephen Korbet; Julia Lewis
Related Documents :
10342479 - Pediatric patients experiencing postoperative nausea and vomiting after burn reconstruc...
11249229 - Where there's hope.
6869349 - Metoclopramide in the treatment of gastric bezoars.
2892729 - Termination of second trimester pregnancy with laminaria and intramuscular 15-methyl pg...
24532009 - Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibact...
17909829 - Microdebrider-assisted partial tonsillectomy: short- and long-term outcomes.
18657739 - Intra-articular sufentanil in multimodal analgesic management after outpatient arthrosc...
16928569 - Progress versus precision: challenges in clinical trial design for left ventricular ass...
22418879 - Quantifying the extent of fistulotomy. how much sphincter can we safely divide? a three...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-16
Journal Detail:
Title:  Nephron. Clinical practice     Volume:  121     ISSN:  1660-2110     ISO Abbreviation:  Nephron Clin Pract     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101159763     Medline TA:  Nephron Clin Pract     Country:  -    
Other Details:
Languages:  ENG     Pagination:  c25-c29     Citation Subset:  -    
Copyright Information:
Copyright © 2012 S. Karger AG, Basel.
Circle Medical Management, Chicago, Ill., USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prevalence of Blepharospasm and Apraxia of Eyelid Opening in Patients with Parkinsonism, Cervical Dy...
Next Document:  Citrullination of TNF-? by peptidylarginine deiminases reduces its capacity to stimulate the product...